BioCentury
ARTICLE | Financial News

BioClin raises $30M in series B

March 22, 2017 9:00 PM UTC

Antibody company BioClin Therapeutics Inc. (San Ramon, Calif.) raised $30 million in a series B round led by new investors Sofinnova Ventures and Ysios Capital. Existing investors HealthCap, LSP and Tekla Capital Management also participated.

The company is conducting a Phase Ib/II study of lead candidate B-701 in combination with docetaxel to treat relapsed or refractory bladder cancer. CEO Stephen Lau told BioCentury that BioClin expects data in 1H18. B-701 is a human IgG1 mAb targeting fibroblast growth factor (FGF) receptor 3 (FGFR3; CD333)...